Patent US4738955A successfully refreshed from Google Patents.
US4738955A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anti-carcinoma therapeutic agent of glycosaminoglycans and cytostatic agents
Assignee: Individual
•
Filing: 1985-08-28
•
Granted: 1988-04-19
•
Expires: 2005-08-28
Abstract
Abstract A combination consisting of a mixture comprising high-molecular and low-molecular glycosaminoglycan polysulfates as well as a cytostatic agent is effective to obtain improved results in selectively killing quiescent tumor cells. This effect may be reinforced by adding a lipolytic and/or proteolytic enzyme.
Inventors
- 👤 Albert Landsberger
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 18:51
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61K38/00; A61K38/16; A61K38/43; A61K38/46; A61K38/48; A61K38/482; A61K38/4826
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
86 words
A therapeutic preparation comprising glycosaminoglycan polysulfates and at least one cytostatic agent in addition to a pharmaceutically acceptable carrier, characterized in that said glycosaminoglycan polysulfates are present as a mixture of high-molecular glycosaminoglycans having a molecular weight within the range from above 5,000 to 15,000 and low-molecular glycosaminoglycan polysulfates having a molecular weight within the range from 1,500 to 5,000 whereby said cytostatic agent is selected from the group consisting of alkylating cytostatic agents, antimetabolites, antagonists of purine and pyrimidine bases, cytostatically effective antibiotics and alkaloids.
Claim 2
Dependent Claim
86 words
A therapeutic preparation comprising glycosaminoglycan polysulfates and at least one cytostatic agent in addition to a pharmaceutically acceptable carrier, characterized in that said glycosaminoglycan polysulfates are present as a mixture of high-molecular glycosaminoglycans having a molecular weight within the range from above 5,000 to 15,000 and low-molecular glycosaminoglycan polysulfates having a molecular weight within the range from 1,500 to 5,000 whereby said cytostatic agent is selected from the group consisting of alkylating cytostatic agents, antimetabolites, antagonists of purine and pyrimidine bases, cytostatically effective antibiotics and alkaloids.
Claim 3
Dependent Claim
25 words
A therapeutic preparation according to claim 1, characterized in that it contains at least one enzyme selected from the group of proteolytic and lipolytic enzymes.
Claim 4
Dependent Claim
42 words
A therapeutic preparation according to claim 1, characterized in that said high-molecular glycosaminoalycan polysulfate has a molecular weight within the range from above 8,000 to 12,000, and said low-molecular glycosaminoglycan polysulfate has a molecular weight within the range from 1,500 to 3,000.
Claim 5
Dependent Claim
24 words
A therapeutic preparation according to claim 1 or claim 2 or claim 3, characterized in that said low-molecular glycosaminoglycan polysulfate is a pentosan polysulfate.
Claim 6
Dependent Claim
18 words
A therapeutic preparation according to claim 2 or claim 3, characterized in that said additional enzyme is trypsin.
Claim 7
Dependent Claim
33 words
A therapeutic preparation according to claim 1 or claim 2 or claim 3, characterized in that the quantitative ratio between high-molecular and low-molecular glycosaminoglycan polysulfates to cytostatic agents ranges from 1:10 to 10:1.
Claim 8
Dependent Claim
15 words
A therapeutic preparation according to claim 4, characterized in that said additional enzyme is trypsin.
Claim 9
Dependent Claim
27 words
A therapeutic preparation according to claim 4, characterized in that the quantitative ratio between high-molecular and low-molecular glycosaminoglycan polysulfates to cytostatic agents ranges from 1:10 to 10:1.
Claim 10
Dependent Claim
27 words
A therapeutic preparation according to claim 6 characterized in that the quantitative ratio between high-molecular and low-molecular glycosaminoglycan polysulfates to cytostatic agents ranges from 1:10 to 10:1.
Claim 11
Dependent Claim
25 words
A therapeutic preparation according to claim 1 wherein said alkylating cytostatic agent is selected from the group consisting of nitrogenous mustard-gas and ethylene imine derivatives.
Claim 12
Dependent Claim
12 words
A therapeutic preparation according to claim 1 wherein said antimetabolite is methotrexate.
Claim 13
Dependent Claim
20 words
A therapeutic preparation according to claim 1 wherein said alkaloids are selected from a group consisting of cholchicine and vincristin.
Claim 14
Dependent Claim
17 words
A therapeutic preparation according to claim 2 characterized in that said pentosan polysulfate is sodium pentosan polysulfate.
References Cited (Backward Citations)
US4029767A
Cited
US4389392A
Cited
GB2062468A
Cited
US4565806A
Cited
DE3220326A1
Cited
GB2131691A
Cited
EP0114589A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-04-19 | 1991-10-19 | 1992-04-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-04-19 | 1995-10-19 | 1996-04-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-04-19 | 1999-10-19 | 2000-04-19 | $7700.00 | Window Closed / Lapsed |